Logo

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Share this
BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Shots:

  • The first patient has been dosed in a P-II cancer vaccine trial evaluating the efficacy- tolerability & safety of BNT111 + Libtayo in combination or as monothx in 120 patients with anti-PD1 r/r unresectable Stage III or IV melanoma in EU. The company also plans to start P-II trial in 2 additional programs with BNT111 in 2021
  • The 1EPs of a trial is ORR & 2EP includes ORR in monothx arms- DoR- & safety. The company holds global commercial rights to BNT111
  • The P-II trial is based on previous results from a P-I Lipo-MERIT dose-escalation trial that demonstrates a favorable safety profile for BNT111 & DOR was observed in patients with melanoma who had progressed following prior checkpoint blockade

  | Ref: Globe Newswire | Image: Hindustan Times

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions